# Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

> **NCT00151203** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Clarithromycin, Lenalidomide, Dexamethasone

## Key facts

- **NCT ID:** NCT00151203
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-04
- **Final completion:** 2020-09-29
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151203, "Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00151203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*